HEALTH PLANS
UNIVERSITY OF UTAH

PRIOR AUTHORIZATION REQUEST FORM
TOPIRAMATE ER SPRINKLE CAPSULES

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: ☐ topiramate extended-release capsules

Dosing/Frequency:_____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
EPILEPSY			
1. Is the member ≥ 2 years of age?	☐	☐	
2. Is the prescribing physician a neurologist or neuro-oncologist?	☐	☐	
3. Does the member have a diagnosis of partial-onset, primary generalized tonic-clonic seizures or seizures associated with Lennox-Gastaut Syndrome?	☐	☐	**Please provide documentation**
4. Has the member tried and failed at least 2 preferred-generic anticonvulsants?	☐	☐	**Please provide documentation**
5. Has the member tried and found to be intolerant to the inactive ingredients in the immediate release topiramate tablets or topiramate sprinkle capsules?	☐	☐	**Please provide documentation**
MIGRAINE PREVENTION			
1. Is the member 12 years of age or older?	☐	☐	
2. Is the prescribing provider a neurologist or headache specialist?	☐	☐	
3. Has the member been diagnosed with episodic OR chronic migraines?	☐	☐	**Please provide documentation**
4. Is the member experiencing moderate to severe migraines that is causing him/her functional impairment (e.g. missed school/work, decreased ability to perform daily activity, etc.)?	☐	☐	**Please provide documentation**
5. Has the possibility of rebound headaches or medication overuse headaches* been considered and discussed?	☐	☐	**Please provide documentation**

*Medications associated with rebound or overuse headaches include: narcotics, caffeine, NSAIDs, and triptans.			
6. Has the member tried and failed or found to have an intolerance/contraindication to topiramate immediate release or sprinkle capsules?	☐	☐	**Please provide documentation**
7. Has the member trialed and failed (≥ 3months) at least 3 of the following oral medications: • Beta blocker • Calcium channel blocker • Antidepressants • Anticonvulsants • ACE inhibitors/ARBs	☐	☐	**Please provide documentation**
8. Has the member received at least 2 injections of Botox® at least 12 weeks apart?	☐	☐	**Please provide documentation**
REAUTHORIZATION			
1. Is the request for reauthorization of therapy?	☐	☐	
2. For epilepsy, does updated documentation show a positive response to therapy?	☐	☐	**Please provide documentation**
3. For migraine prevention, does updated documentation show a positive response to therapy, defined as a ≥ 50% reduction in headache frequency and/or ≥ 50% reduction in intensity as seen by a decreased need for acute treatment, missed days of school/work, or increase in ability to perform daily activities?	☐	☐	**Please provide documentation**
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 074
Origination Date: 10/12/2018
Reviewed/Revised Date: 08/19/2020
Next Review Date: 08/19/2021
Current Effective Date: 09/01/2020